Clinical Trial Update: A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial evaluating Itepekimab, an anti-IL-33 monoclonal antibody, for efficacy, safety and tolerability in non-cystic fibrosis bronchie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• itepekimab (itepekimab)

Snippet

Sponsor: Sanofi | Conditions: Bronchiectasis | Phase 2 | Status: COMPLETED